Upregulation of CDO1 by theaflavin-3,3′-gallate induces apoptosis and inhibits cell proliferation in TNBC
International Immunopharmacology · 2026-09 · 185 · 117016
DOI: 10.1016/j.intimp.2026.117016 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-09. Verfasst von Wenmei Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, 19 Nonglinxia Road, …. Hauptthemen laut MEDLINE: Catechin, Biflavonoids, Triple Negative Breast Neoplasms, Cysteine Dioxygenase. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited treatment options due to the absence of targetable receptors. Theaflavin-3,3'-gallate (TF-3), a polyphenol abundant in black tea, has demonstrated anticancer activity across multiple cancer types, including prostate and ovarian cancers, suggesting its potential as a broad-spectrum antitumor agent. However, the specific mechanisms underlying its effects in breast cancer remain to be fully elucidated. In this study, we show that TF-3 significantly inhibits TNBC cell proliferation, migration, and colony formation while inducing apoptosis in a dose-dependent manner. Transcriptomic analysis revealed that these antitumor effects are accompanied by upregulation of cysteine dioxygenase type 1 (CDO1), suggesting its potential involvement. Metabolomic profiling demonstrated that TF-3 treatment profoundly reprograms the TNBC metabolome, with amino acid and lipid metabolism pathways being primary targets. Functional experiments showed that CDO1 knockdown partially attenuates TF-3 induced apoptosis, whereas CDO1 overexpression enhances caspase-3/9 activation, indicating a contributory rather than exclusive role for CDO1. Furthermore, bioinformatic analyses identified CDO1 as a potential diagnostic and prognostic biomarker, with its expression correlating with immune cell infiltration (particularly macrophages and T cells) in the tumor microenvironment; however, these associations are correlative and require experimental validation. Collectively, our findings establish TF-3 as a promising therapeutic candidate for TNBC and underscore the critical involvement of CDO1 in its antitumor effects, providing a foundation for future combination strategies targeting metabolism and immune modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, First School of Clinical Medicine, The First Affiliated Hospital of Guangdong Pharmaceutical University, 19 Nonglinxia Road, Yuexiu District, Guangzhou 510080, China; Guangdong Provincial Key Lab…
- Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, School of Life Sciences and Biopharmaceuticals, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- School of Health Sciences, Guangzhou Xinhua University, Guangzhou 51000, China. Electronic address: huaqinli1021@xhsysu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, W., Huang, B., Liu, H., Lin, L., Zhao, Y., Zhang, J., Li, H., & Zhu, J. (2026). Upregulation of CDO1 by theaflavin-3,3′-gallate induces apoptosis and inhibits cell proliferation in TNBC. International Immunopharmacology, 185, 117016. https://doi.org/10.1016/j.intimp.2026.117016
Vancouver
Wu W, Huang B, Liu H, Lin L, Zhao Y, Zhang J, et al. Upregulation of CDO1 by theaflavin-3,3′-gallate induces apoptosis and inhibits cell proliferation in TNBC. International Immunopharmacology. 2026;185:117016. doi:10.1016/j.intimp.2026.117016
BibTeX
@article{Wu2026,
author = {Wu, Wenmei and Huang, Botian and Liu, Huoxi and Lin, Luobin and Zhao, Yuntao and Zhang, Jiayang and Li, Huaqin and Zhu, Jinrong},
title = {Upregulation of CDO1 by theaflavin-3,3′-gallate induces apoptosis and inhibits cell proliferation in TNBC},
journal = {International Immunopharmacology},
year = {2026},
volume = {185},
pages = {117016},
doi = {10.1016/j.intimp.2026.117016}
}
EUVIMED